TPMT and hyperinsulinemic hypoglycemia, familial, 4: Based on the risk of myelosuppression, Food and Drug Administration (FDA) and the Clinical Pharmacogenetics Implementation Consortium recommend genotyping or phenotyping for thiopurine S-methyltransferase (TPMT) deficiency prior to starting thiopurines [17,18,19].